Eisai and Biogen can finally put their European regulatory uncertainty surrounding Alzheimer's disease medicine Leqembi ...

Leqembi approved by the EU for early-stage Alzheimer’s in patients with specific ApoE4 gene profile, marking a milestone in ...

Cullinan Therapeutics (CGEM) announced that the European Medicines Agency, EMA, approved the Company’s Clinical Trial Application, CTA, for ...

The antibody lecanemab is the first authorized therapy in Europe that targets the underlying process of Alzheimer's, rather than only treating symptoms.

Raw material dependency and transport bottlenecks, not just production capacity, are the key challenges facing the EU's radiopharmaceutical sector, according to the European Medicines Agency (EMA). Vi ...

Most patients who enroll in the Lung-MAP precision medicine trial in non-small cell lung cancer can now be matched to a targeted investigational treatment based on the results of their prior genomic ...

NanoViricides, Inc., a publicly traded company (NYSE Amer.:NNVC) (the “Company”), and a leading global pioneer in the development of broad-spectrum antivirals based on host-mimetic nanomedicine ...

Following a turbulent period marked by Brexit and the pandemic, Ben Hargreaves finds the agency aiming to streamline processes and improve collaboration with applicants. The European Medicines ...

The European Medicines Agency's PRIME (PRIority MEdicines) initiative is a clear attempt to match the US FDA's Breakthrough Therapy Designation, which has been in place since 2012 and has ...

The “Symposium on Artificial Intelligence and Pharmacology – Present and Future” will be held on June 3rd, 2025, in Copenhagen, bringing together 140 persons across disciplines to foster collaboration ...

CHMP reversed its initial recommendation for the EC to not authorize the drug due to the risk of side effects like ARIA.